Skip to content
Peptide research

Zinc Thymulin (ZnFTS)

Also known as Facteur Thymique Serique · Thymulin
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

A zinc-bound form of thymulin, a thymic hormone that is inactive without zinc, promoted for immune restoration and hair regrowth. The zinc-deficiency study supports zinc repletion to restore endogenous thymulin activity, rather than treatment with exogenous zinc-thymulin. Most other evidence is animal or mechanistic, so the human case is weak. Human safety evidence includes a small topical pilot; this does not establish injectable or long-term safety, and its immune-stimulating action poses a theoretical autoimmune risk. Not an approved drug in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Zinc Thymulin (ZnFTS) is a 9-amino-acid hormone produced exclusively by the thymus gland, first characterized in a landmark 1977 Nature paper by Bach and Dardenne. It is unique among thymic hormones because it absolutely requires zinc to function — without zinc bound to it in a 1:1 ratio, the peptide is completely inactive. As both the thymus shrinks and zinc levels drop with age, thymulin levels decline dramatically, contributing to weakened immunity in older adults. It is also being studied topically for hair loss.

How it works in the body

Thymulin is a nonapeptide hormone produced by thymic epithelial cells that requires zinc binding to be biologically active. The zinc-thymulin complex binds to specific receptors on T cell precursors, promoting their differentiation into mature T cells and modulating the balance between different T cell subsets.

Research overview

Zinc Thymulin is the only thymic hormone whose exclusive origin from the thymus has been definitively proven. It promotes T-cell maturation, enhances natural killer cell activity, and regulates interleukin-2 production. Prasad's 1988 study in the Journal of Clinical Investigation established it as one of the most sensitive biomarkers of zinc status in the body — even mild zinc deficiency causes thymulin to drop, and supplementing zinc restores it along with T-cell function. Beyond immunity, thymulin and its synthetic analogue PAT show potent pain-relieving and anti-inflammatory effects, equaling or exceeding dexamethasone in some models. A clinical study of topical zinc-thymulin for hair loss showed significant increases in hair counts after six months. Gene therapy approaches have restored thymulin levels long-term in animals without a thymus. Research is published in high-caliber journals (Nature, JCI, British Journal of Pharmacology). Historical randomized trials of synthetic thymulin exist, but they do not establish benefit for hair loss or immune aging, and the hair loss study was a small open-label pilot (n=18).

Who researches Zinc Thymulin (ZnFTS)?

Commonly researched by

  • People researching hair restoration options

    Explored for effects on hair follicle stimulation or hair regrowth.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People exploring pain management options

    Researched for analgesic or pain-modulating properties.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • No Phase I safety trials conducted in humans

    High

    Absence of registered Phase I trials on ClinicalTrials.gov; historical FTS clinical use predates modern trial standards

  • Immune-stimulating; theoretical autoimmune aggravation

    Theoretical

    Mechanistic inference from thymulin immunomodulatory literature (Mocchegiani/Dardenne reviews)

  • Injection site irritation

    Low

    Class effect for injected thymic peptides; thymosin-alpha1 clinical adverse-effect data

  • No reproductive toxicology studies conducted

    Moderate

    No identifiable published reproductive toxicology; thymulin-gonadotropin interaction literature (Goya group)

  • Crosses into brain tissue; documented CNS activity

    Low

    Thymulin i.c.v. (direct central) CNS-activity studies (PMID 14580936; PMID 21059360); note: these do not establish peripheral BBB crossing

Interaction summary(6)

Rated by direction with this peptide

  • Zinc (dietary or supplemental)

    SynergisticModerate

    Thymulin is biologically inactive without bound zinc, so adequate zinc status is required for and directly potentiates its T-cell activity; zinc deficiency renders it inert.

    Prasad, Serum thymulin in human zinc deficiency (PMC442670); Mocchegiani review (PMC2702361)

  • Zinc-depleting or chelating agents (penicillamine, high-dose iron/calcium, thiazide diuretics)

    CautionLow

    Drugs that chelate zinc or increase its urinary loss can lower the zinc pool needed for thymulin activation, theoretically blunting its effect.

    Mechanistic, based on zinc-dependence of thymulin (Prasad, PMC442670)

  • Immunosuppressants / calcineurin inhibitors (cyclosporine, tacrolimus, transplant regimens)

    CautionTheoretical

    Its immunorestorative, T-cell-promoting action could theoretically oppose intended immunosuppression, which would be undesirable in transplant or autoimmune therapy.

    Mechanistic inference from thymulin immunomodulatory action

  • Corticosteroids / glucocorticoids

    CautionTheoretical

    Pharmacologic glucocorticoid doses suppress endogenous thymic thymulin output and broadly immunosuppress, working against thymulin's immunorestorative effect (the relationship is bidirectional and dose-dependent).

    Mechanistic; glucocorticoid-thymic function literature (Dardenne/Mocchegiani reviews)

  • Immune checkpoint inhibitors / immunostimulatory biologics

    CautionTheoretical

    Additive immune activation could theoretically raise the risk of immune-related adverse events or autoimmunity when combined with agents that already amplify T-cell responses.

    Mechanistic inference from combined immune-stimulatory effects

  • Vaccines

    SynergisticTheoretical

    By supporting T-cell differentiation and function, thymulin (or correction of the zinc-thymulin axis) could enhance T-cell-dependent vaccine responses, particularly in zinc-deficient or immunosenescent elderly.

    Extrapolated from zinc-thymulin immune-restoration data in the elderly (PMID 8460613; PMC2702361)

Known risks(5)

  • Limited human safety data

    Moderate

    No Phase I safety trials have been conducted for zinc thymulin in humans. Safety data comes from the Vickers alopecia study (3,300 treatment days, no adverse events with topical use) and decades of in vitro/animal research showing good tolerability. However, the absence of formal pharmacovigilance data for injectable use means unknown adverse effects cannot be excluded, especially with prolonged use or in sensitive populations.

  • Potential autoimmune exacerbation

    Moderate

    As an immune-stimulating agent that promotes T-cell differentiation and enhances T-cell subset functions, thymulin could theoretically exacerbate autoimmune conditions. Individuals with active autoimmune diseases requiring immunosuppression should avoid thymulin. This risk is theoretical based on mechanism of action rather than observed clinical events.

  • Injection site reactions

    Low

    Subcutaneous or intramuscular injection of thymulin may cause transient mild irritation, redness, or discomfort at the injection site. This is consistent with the general profile of injectable peptides and has been reported anecdotally but not systematically studied for zinc thymulin specifically.

  • Unknown effects in pregnancy and lactation

    High (precautionary)

    No reproductive toxicology studies have been conducted for zinc thymulin. Given its immunomodulatory mechanism and effects on T-cell differentiation, use during pregnancy and lactation should be avoided as a precautionary measure until safety data are available.

  • Potential mood or CNS effects at high doses

    Low

    Thymulin has documented CNS activity — it crosses into brain tissue, modulates cytokine levels in specific brain regions, and affects the hypothalamic-pituitary axis (including ACTH and gonadotropin regulation). Clinical significance is uncertain.

Drug interactions(5)

  • Immunosuppressants (cyclosporine, tacrolimus, corticosteroids)

    Thymulin promotes T-cell differentiation and enhances immune function, which may counteract the therapeutic effects of immunosuppressive drugs. Concurrent use could reduce the efficacy of immunosuppression in transplant recipients or autoimmune disease management. Avoid concurrent use or use only under close medical supervision.

  • Minoxidil and Finasteride (hair loss treatments)

    The Vickers 2017 study reported that three subjects using concurrent minoxidil (n=2) or minoxidil plus finasteride (n=1) experienced no drug interactions with topical zinc-thymulin. Limited data but no signal of interaction for topical co-administration in alopecia treatment.

  • Vaccines (live and inactivated)

    Thymulin's T-cell stimulatory effects could theoretically modulate vaccine immune responses. The direction of this effect is uncertain — enhanced T-cell function might improve vaccine immunogenicity, but timing and dose considerations are unknown. Consider spacing thymulin administration and vaccination; consult with a physician.

  • Zinc supplements

    Exogenous zinc supplementation alongside zinc thymulin may lead to excessive zinc intake. Since thymulin requires zinc in a 1:1 ratio for activity, and the peptide preparation itself contains zinc, additional zinc supplementation should be calibrated to total zinc intake to avoid zinc toxicity (nausea, copper depletion, immune impairment at very high doses).

  • Other thymic peptides (thymosin alpha-1, thymalin, thymogen)

    Combining multiple thymic peptides may produce additive or unpredictable immunomodulatory effects. Anecdotal reports of restlessness and mood instability when thymic peptides are combined with neuroactive peptides like Epitalon suggest potential CNS interactions. No formal interaction studies exist for thymic peptide combinations.

Research & benefits

Evidence base

Evidence Level
Mostly Preclinical
Total Studies
30
Human Studies
3

Zinc thymulin has a robust preclinical evidence base spanning in vitro, animal, and limited human studies, published in high-impact peer-reviewed journals including Nature, Journal of Clinical Investigation, and British Journal of Pharmacology. The immunological mechanism of action is well-characterized: thymulin requires zinc for activity, promotes T-cell differentiation, and serves as a sensitive biomarker of zinc status. Human evidence includes Prasad's 1988 JCI study demonstrating zinc-dependent thymulin restoration in zinc-deficient adults, and the Vickers 2017 pilot study showing topical efficacy in androgenetic alopecia (n=18, open-label, no placebo control). Historical randomized placebo-controlled trials tested synthetic thymulin, called nonathymulin, in rheumatoid arthritis. Those studies do not establish efficacy of contemporary zinc-thymulin products for hair loss or immune aging. Analgesic and neuroprotective effects are supported by multiple animal studies but no human pain trials. Gene therapy restoration of thymulin has been demonstrated in thymectomized rodents only. No studies are registered on ClinicalTrials.gov for any indication. The fundamental science is strong, but translational clinical evidence remains limited.

Researched for(6)

Rated by confidence in the evidence

  • Restoration of endogenous thymulin activity during zinc repletion; this study did not test exogenous zinc-thymulin treatment

    Medium

    Human trials show zinc repletion restores thymulin activity and corrects T-cell measures in deficient adults.

    Prasad et al., Serum thymulin in human zinc deficiency (PMC442670); Fabris/Mocchegiani, physiological zinc supplementation in elderly, thymic status (PMID 8460613); Mocchegiani review, immune system and zinc in aging (PMC2702361)

  • Promotion of hair growth in androgenetic alopecia

    Speculative

    One small unblinded 2017 pilot of topical zinc-thymulin reported less shedding, with no controlled replication.

    Vickers ER, An Analysis of the Safety and Efficacy of Topical Zinc-Thymulin to treat Androgenetic Alopecia, Hair Ther Transplant 2017;7:147 (doi 10.4172/2167-0951.1000147); mechanistic support: Meier et al., thymic peptides modulate human hair follicle growth in organ culture, 2012

  • Analgesic and anti-inflammatory effects comparable to standard drugs

    Low

    In rat models a thymulin analogue matched standard anti-inflammatory drugs, with no human testing yet.

    Safieh-Garabedian et al., Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat, Br J Pharmacol 2002;136:947-55 (PMID 12110619)

  • Neuroprotection against endotoxin-induced central nervous system inflammation

    Low

    Rat studies show thymulin lowers brain inflammation after endotoxin, but human evidence is absent.

    Safieh-Garabedian et al., Thymulin reverses inflammatory hyperalgesia after i.c.v. endotoxin, Neuroscience 2003 (PMID 14580936); Thymulin-related peptide attenuates brain inflammation after i.c.v. endotoxin, 2010 (PMID 21059360)

  • Restoration of T-lymphocyte differentiation in malnourished children

    Low

    In lab tests thymulin matured T-cells from malnourished children, but no treatment trial exists.

    In vitro lymphocyte-differentiating effects of thymulin (Zn-FTS) on lymphocyte subpopulations of severely malnourished children, Am J Clin Nutr; Thymulin (Zn-FTS) activity in protein-energy malnutrition (PMID 3124594); Serum thymic hormone activity in PEM (PMID 118837)

  • Long-term restoration of circulating thymulin via gene therapy

    Low

    One gene-therapy injection restored normal thymulin for months in mice and rats, with no human data.

    Reggiani/Goya et al., Gene therapy for long-term restoration of circulating thymulin in thymectomized mice and rats, Gene Therapy 2006 (PMID 16617301)

Benefits(6)

  • Zinc repletion restores endogenous thymulin activity and some T-cell measures in zinc-deficient people; this study did not test treatment with exogenous zinc-thymulin

    Prasad et al. 1988 (Journal of Clinical Investigation, PMID 3262625) — In three human models of mild zinc deficiency (dietary-induced in volunteers, sickle cell anemia patients, and non-SCA zinc-deficient adults), serum thymulin activity was significantly decreased and was restored by both in vivo and in vitro zinc supplementation. T-cell abnormalities including increased T101-/sIg- cells, decreased T4+/T8+ ratio, and reduced IL-2 activity were all corrected after zinc repletion. Establishes thymulin as the mechanistic link between zinc status and T-cell function.

  • Promotion of hair growth in androgenetic alopecia

    Vickers 2017 (Hair Therapy & Transplantation, DOI: 10.4172/2167-0951.1000147) — In 18 adult subjects (17 male, 1 female, age 35-90) with androgenetic alopecia (Norwood 2-7), topical zinc-thymulin spray applied for 4-10 months produced a 32% increase in vellus hair count and 23% increase in intermediate hair count at 6 months. Significantly less 'absent hair' after treatment (P=0.008) and significant increase of intermediate hair (P=0.02). No adverse systemic or local side effects across 3,300 treatment days. Compatible with concurrent minoxidil and finasteride use.

  • Analgesic and anti-inflammatory effects comparable to standard drugs

    Safieh-Garabedian et al. 2002 (British Journal of Pharmacology, PMID 12110619) — PAT (peptide analogue of thymulin) decreased mechanical and thermal hyperalgesia in rat inflammatory models in a dose-dependent manner, with analgesic actions equal to or stronger than dexamethasone and indomethacin at much lower concentrations. Thymulin-related peptides reduced levels of IL-1beta, IL-6, and NGF in inflamed tissue. Confirmed by 2019 study (Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways) showing thymulin reduced CFA-induced microglial activation, p38 MAPK phosphorylation, and spinal TNF-alpha and IL-6 production.

  • Neuroprotection against endotoxin-induced central nervous system inflammation

    Dardenne et al. 2006 (Annals of the New York Academy of Sciences, PMID 17192563) — Pretreatment with thymulin reduced endotoxin-induced hyperalgesia in a dose-dependent manner and exerted differential effects on upregulated levels of IL-6 and IL-1beta across specific brain tissue regions, restoring near-normal cytokine levels. Suggests thymulin modulates cytokine-neuronal cross-talk and interferes with CNS cytokine signaling during inflammatory stress, demonstrating a neuroprotective role beyond its classical immune function.

  • Restoration of T-lymphocyte differentiation in malnourished children

    Chevalier et al. 1994 (American Journal of Clinical Nutrition, PMID 8030607) — In vitro incubation of lymphocytes from severely malnourished children with thymulin (Zn-FTS) decreased immature T-lymphocytes and increased mature T-lymphocytes. Children with severe protein-energy malnutrition (marasmus, kwashiorkor, marasmic kwashiorkor) displayed high T-lymphocyte immaturity correlating with severe thymic involution. Thymulin partially reversed these defects in vitro, demonstrating its potential for immune restoration in vulnerable populations.

  • Long-term restoration of circulating thymulin via gene therapy

    Goya et al. 2006 (Gene Therapy / Nature, PMID 16617301) — Intramuscular injection of an adenoviral vector (RAd-metFTS) encoding a biologically active thymulin analog (met-FTS) in thymectomized mice and rats restored circulating thymulin levels to normal values for several months. Transduced myocytes acted as an ectopic thymulin source. Demonstrates feasibility of gene-therapy-based restoration of thymic endocrine function for aging and thymus-deficient states.

Key studies(5)

  1. Biochemical characterisation of a serum thymic factor

    Biochemical characterization (landmark discovery)N/A (biochemical isolation and characterization)

    Bach JF, Dardenne M, Pleau JM, Rosa J

    Nature

    1977

    First biochemical characterization of serum thymic factor (FTS/thymulin). The factor was isolated from porcine serum, its nonapeptide amino acid sequence (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) was determined, and the synthetic peptide was shown to be fully biologically active. Established that this serum factor is thymus-derived and induces T-cell differentiation. This paper launched the entire field of thymulin research.

  2. Serum thymulin in human zinc deficiency

    Human clinical study (three models of zinc deficiency)14 subjects (2 dietary-induced, 6 sickle cell anemia, 6 non-SCA zinc-deficient)Zinc depletion followed by repletion phases

    Prasad AS, Meftah S, Abdallah J, Kaplan J, Brewer GJ, Bach JF, Dardenne M

    Journal of Clinical Investigation

    1988

    Serum thymulin activity was significantly decreased in all three models of mild zinc deficiency and was corrected by both in vivo and in vitro zinc supplementation. T-cell abnormalities (increased T101-/sIg- cells, decreased T4+/T8+ ratio, reduced IL-2 activity) were corrected after zinc repletion. Established thymulin as a sensitive biomarker of zinc status and provided the mechanistic link between zinc deficiency and T-cell dysfunction.

  3. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat

    Experimental animal study (rat, inflammatory pain models)Multiple rat cohorts across inflammatory and neuropathic pain modelsAcute experiments with multiple dosing schedules

    Safieh-Garabedian B, Dardenne M, Pléau JM, Saadé NE

    British Journal of Pharmacology

    2002

    PAT (peptide analogue of thymulin) decreased mechanical and thermal hyperalgesia in dose-dependent fashion. Analgesic potency was equal to or greater than dexamethasone and indomethacin at substantially lower concentrations. PAT reduced levels of IL-1beta, IL-6, and NGF in inflamed tissue, establishing thymulin-related peptides as a novel class of analgesic molecules with anti-inflammatory mechanisms distinct from NSAIDs and steroids.

  4. An Analysis of the Safety and Efficacy of Topical Zinc-Thymulin to treat Androgenetic Alopecia

    Open-label pilot clinical study (human)18 subjects (17 male, 1 female; age 35-90; Norwood 2-7)4-10 months treatment; primary endpoint at 6 months

    Vickers ER

    Hair Therapy & Transplantation

    2017

    Topical zinc-thymulin water-based spray produced a 32% increase in vellus hair count and 23% increase in intermediate hair count at 6 months. Significantly less 'absent hair' after treatment (P=0.008) and significant increase of intermediate hair in baseline/after treatment (P=0.02). VAS hair assessment improvement was significant at 6 months (P=0.045). Across 3,300 treatment days, no adverse systemic or local side effects. Three subjects concurrently using minoxidil and/or finasteride reported no drug interactions.

  5. Gene therapy for long-term restoration of circulating thymulin in thymectomized mice and rats

    Experimental gene therapy study (mice and rats)Thymectomized mice (nude and surgically thymectomized) and ratsSeveral months of follow-up post-injection

    Reggiani PC, Hereñú CB, Rimoldi OJ, Brown OA, Pléau JM, Dardenne M, Goya RG

    Gene Therapy (Nature Publishing Group)

    2006

    Intramuscular injection of adenoviral vector RAd-metFTS encoding a biologically active thymulin analog (met-FTS) restored circulating thymulin levels to normal values in thymectomized and nude mice as well as thymectomized rats. The restorative effect was long-lasting (several months). Transduced myocytes served as an ectopic source of thymulin, demonstrating proof-of-concept for gene-therapy-based restoration of thymic endocrine function in aging and thymus-deficient states.

Regulation & availability

Why researchers look at it

Prasad's 1988 study in the Journal of Clinical Investigation established that even mild zinc deficiency causes thymulin to plummet, and supplementation restores it along with T-cell function — connecting two well-known age-related declines (thymus shrinkage and dropping zinc levels) in a single molecule. A pilot study (n=18) also showed significant hair count increases after six months of topical application. Larger controlled trials could bridge the gap between immune aging research and practical clinical use.

FDA status
Not FDA-approved. Zinc thymulin has never been the subject of an IND application, NDA, or Biologics License Application (BLA) with the US FDA. It is not listed as an approved drug, an investigational drug, or a Generally Recognized as Safe (GRAS) substance. Thymulin acetate is in FDA's 503A bulk drug substance Category 3. It is not a controlled substance under the Controlled Substances Act. The FDA has not issued specific guidance or warning letters regarding zinc thymulin, though the agency has taken enforcement actions against other compounded peptides (e.g., thymosin alpha-1) and the broader regulatory environment for compounded peptides remains unsettled following FDA actions in 2023-2025 regarding peptide compounding under sections 503A and 503B of the FD&C Act.
WADA status
Zinc-thymulin is not named on the 2026 List. S0 prohibits pharmacological substances not addressed elsewhere on the List that lack current governmental approval for human therapeutic use. Without a verified authorization, its status should be checked with the relevant anti-doping authority.
Prescribability
Zinc Thymulin is NOT FDA-approved for any therapeutic indication in the United States. No Investigational New Drug (IND) application or New Drug Application (NDA) has been filed with the FDA for zinc thymulin. It is not a controlled substance under US federal law. Some compounding pharmacies and anti-aging or integrative medicine clinics offer zinc thymulin preparations (topical or injectable), particularly for hair loss, but a listing does not establish lawful compounding eligibility: thymulin acetate is in 503A Category 3, thymulin does not have a USP monograph, and no qualifying US bulk-compounding pathway for zinc-thymulin was identified. Topical zinc-thymulin hair products are marketed by some specialty brands as cosmetic or wellness products rather than drugs. Some longevity and integrative medicine physicians prescribe zinc thymulin subcutaneously for immune modulation and anti-aging purposes, but this is use of an unapproved drug outside standard Western medical practice. No country has granted full pharmaceutical approval specifically for zinc thymulin as a standalone drug product.
Availability
Zinc thymulin is not approved as a pharmaceutical drug in any major regulatory jurisdiction, and thymulin lacks a USP monograph. Topical zinc-thymulin products for hair loss are marketed by specialty brands, sometimes as cosmetic formulations rather than drugs. Some clinics advertise topical or injectable preparations, but a listing does not establish lawful compounding eligibility. Thymulin acetate is in 503A Category 3, and no qualifying US bulk-compounding pathway for zinc-thymulin was identified. The small human hair study used a topical formulation. International availability varies; thymulin is not scheduled as a controlled substance in the US, Australia, or New Zealand.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(10)

  1. 1977
    Bach, Dardenne, Pleau, and Rosa publish biochemical characterization of serum thymic factor (FTS/thymulin) in Nature, establishing its nonapeptide sequence and thymic origin.
  2. 1977-1983
    Zinc dependency of thymulin established; NMR structural studies confirm zinc-induced conformational change; monoclonal antibody-defined epitope characterized. Studies on zinc binding kinetics published (Kd ~5 x 10^-7 M).
  3. 1988
    Prasad et al. publish definitive human study in Journal of Clinical Investigation demonstrating that serum thymulin is a sensitive biomarker of zinc deficiency and that zinc supplementation restores thymulin activity and corrects T-cell abnormalities.
  4. 1989
    Bach and Dardenne publish comprehensive review 'Thymulin, a zinc-dependent hormone' in Medical Oncology, establishing thymulin as the best-characterized thymic hormone with proven endocrine function.
  5. 1994
    Chevalier et al. demonstrate in vitro lymphocyte-differentiating effects of thymulin in severely malnourished children, published in American Journal of Clinical Nutrition.
  6. 2002
    Safieh-Garabedian et al. discover potent analgesic and anti-inflammatory actions of PAT (peptide analogue of thymulin) in rat pain models, published in British Journal of Pharmacology.
  7. 2006
    Goya et al. achieve long-term gene-therapy-based restoration of circulating thymulin in thymectomized mice and rats using adenoviral vector RAd-metFTS, published in Gene Therapy (Nature Publishing Group).
  8. 2017
    Vickers publishes an uncontrolled 18-person topical zinc-thymulin pilot in Hair Therapy & Transplantation, reporting hair-growth changes and one transient episode of forehead redness attributed to the formulation's citric acid buffer.
  9. 2019
    Thymulin's spinal anti-inflammatory mechanisms characterized — shown to reduce microglial activation, p38 MAPK phosphorylation, and spinal pro-inflammatory cytokine production in inflammatory pain models.
  10. 2023-2026
    Zinc thymulin remains without FDA approval or formal clinical development in the US/EU. The broader FDA regulatory crackdown on compounded peptides (2023-2025) affects the landscape for clinic-compounded thymulin preparations.

Sources & FAQs

Research sources(13)

Frequently asked questions(5)

What is the difference between thymulin, thymalin, thymosin alpha-1, and thymosin beta-4?

These are distinct molecules despite similar names. Thymulin (ZnFTS) is a specific nonapeptide (9 amino acids) produced by thymic epithelial cells, requiring zinc for activity — discovered by Bach and Dardenne. Thymalin is a polypeptide complex extracted from calf thymus glands, developed by Khavinson in Russia — it contains a mixture of many short peptides. Thymosin alpha-1 is a 28-amino-acid peptide (marketed as Zadaxin) with FDA orphan drug designation. Thymosin beta-4 is a 43-amino-acid peptide involved in tissue repair. FDA identifies TB-500 as its seven-amino-acid LKKTETQ fragment. WADA prohibits thymosin beta-4 and its derivatives, including TB-500. Each has distinct structure, mechanism, and regulatory status.

Why does thymulin require zinc to function?

Thymulin in its zinc-free form (apothymulin) is biologically inactive. Zinc binds to the nonapeptide in a 1:1 equimolecular ratio with an affinity constant (Kd) of approximately 5 x 10^-7 M, inducing a specific three-dimensional conformation required for receptor binding and biological activity. This conformation has been confirmed by NMR studies and is recognized by conformation-specific monoclonal antibodies. This zinc dependency means that systemic zinc deficiency — which is common in aging, malnutrition, and chronic illness — directly impairs thymulin function even if the peptide is produced normally by the thymus.

Can zinc thymulin help with hair loss?

One open-label pilot study (Vickers et al. 2017, n=18) reported that topical zinc-thymulin spray increased vellus hair count by 32% and intermediate hair count by 23% after 6 months in subjects with androgenetic alopecia, with no adverse effects across 3,300 treatment days. These results are promising but preliminary — the study lacked a placebo control group and was small. Larger randomized controlled trials are needed to confirm efficacy. The proposed mechanism involves thymulin's immunomodulatory effects reducing follicular inflammation and zinc supporting follicle health.

How does thymulin relate to aging and immune decline?

The thymus begins involuting after puberty, and by age 60-70, thymic function is dramatically reduced. Circulating thymulin levels decline in parallel with thymic involution — additionally, age-related zinc deficiency further reduces thymulin activity by depleting the zinc required for the peptide's biological function. This double decline (less thymulin production plus less zinc availability) contributes to immunosenescence: reduced naive T-cell output, impaired immune surveillance, poor vaccine responses, and increased infection and cancer susceptibility. Restoring zinc-thymulin levels is a proposed strategy for partially reversing age-related immune decline.

Is zinc thymulin the same as taking a zinc supplement?

No. Zinc supplementation can restore the activity of endogenous thymulin that exists in its inactive apothymulin form due to zinc deficiency — Prasad's 1988 JCI study demonstrated this clearly. However, zinc supplementation alone cannot compensate for reduced thymulin production caused by thymic involution in aging. Exogenous zinc thymulin provides both the peptide and the zinc together, which is relevant when thymic production of the peptide itself has declined. For younger individuals who are simply zinc-deficient, zinc supplementation alone may be sufficient to restore endogenous thymulin activity.